Alvarez Secord, A., Barroilhet, L., Cheol Lim, M., Oosman, S., Gupta, S., Jada, S., … O’Malley, D. (2022). TP021/#1521 FLORA-5/GOG3035: chemo-immunotherapy (paclitaxel and carboplatin ± oregovomab) as front-line treatment for patients with ovarian cancer. A phase III double blind placebo controlled, global multicenter study. In E-Posters (Trials In Progress) (p. A233.2-A234). BMJ Publishing Group Ltd. https://doi.org/10.1136/ijgc-2022-igcs.530

Alvarez Secord, Angeles, Lisa Barroilhet, Myong Cheol Lim, Sonia Oosman, Sunil Gupta, Srinivasa Jada, Michael Gold, et al. “TP021/#1521 FLORA-5/GOG3035: chemo-immunotherapy (paclitaxel and carboplatin ± oregovomab) as front-line treatment for patients with ovarian cancer. A phase III double blind placebo controlled, global multicenter study.” In E-Posters (Trials In Progress), A233.2-A234. BMJ Publishing Group Ltd, 2022. https://doi.org/10.1136/ijgc-2022-igcs.530.

Alvarez Secord A, Barroilhet L, Cheol Lim M, Oosman S, Gupta S, Jada S, et al. TP021/#1521 FLORA-5/GOG3035: chemo-immunotherapy (paclitaxel and carboplatin ± oregovomab) as front-line treatment for patients with ovarian cancer. A phase III double blind placebo controlled, global multicenter study. In: E-Posters (Trials In Progress). BMJ Publishing Group Ltd; 2022. p. A233.2-A234.

Alvarez Secord, Angeles, et al. “TP021/#1521 FLORA-5/GOG3035: chemo-immunotherapy (paclitaxel and carboplatin ± oregovomab) as front-line treatment for patients with ovarian cancer. A phase III double blind placebo controlled, global multicenter study.” E-Posters (Trials In Progress), BMJ Publishing Group Ltd, 2022, p. A233.2-A234. Crossref, doi:10.1136/ijgc-2022-igcs.530.

Alvarez Secord A, Barroilhet L, Cheol Lim M, Oosman S, Gupta S, Jada S, Gold M, Gilbert L, Barlin J, Edraki B, Tewari D, Provencher D, Kim YM, Bixel K, O’Malley D. TP021/#1521 FLORA-5/GOG3035: chemo-immunotherapy (paclitaxel and carboplatin ± oregovomab) as front-line treatment for patients with ovarian cancer. A phase III double blind placebo controlled, global multicenter study. E-Posters (Trials In Progress). BMJ Publishing Group Ltd; 2022. p. A233.2-A234.